• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

The OVATION 3 Study Initiates First Trial Site for Ovarian Cancer

by MM360 Staff | May 8, 2025 | Uncategorized

Source: CureToday articles The first trial site has been initiated in the pivotal phase 3 OVATION 3 study which will investigate IMNN-001 for newly diagnosed advanced ovarian cancer. Read More

FDA Approves Avmapki Fakzynja Co-pack for KRAS Serous Ovarian Cancer

by MM360 Staff | May 8, 2025 | Uncategorized

Source: CureToday articles Treatment with the Avmapki Fakzynja Co-pack received accelerated FDA approval for previously treated low-grade serous ovarian cancer with KRAS mutations. Read More

Celebrating Nurses Week: The Heart and Soul of Our Cancer Community

by MM360 Staff | May 8, 2025 | Uncategorized

Source: CureToday articles I’m 22 years out from breast cancer and forever grateful for the nurses who gave me not just treatment but friendship, laughter and a community of hope. Read More

Danyelza Added to NCCN Guidelines for High-Risk Neuroblastoma

by MM360 Staff | May 8, 2025 | Uncategorized

Source: CureToday articles Danyelza is now a recommended treatment in NCCN guidelines for relapsed or refractory high-risk neuroblastoma, a type of brain cancer. Read More

Navigating Lymphoma and Survivorship in Adolescents and Young Adults

by MM360 Staff | May 8, 2025 | Uncategorized

Source: CureToday articles Dr. Kara Kelly discusses the unique challenges that adolescent and young adult patients with cancer face following their diagnosis. Read More

EMERALD Trial Results: What Prior CDK4/6i Duration Means for Treatment Success

by MM360 Staff | May 8, 2025 | Uncategorized

Source: CureToday articles Panelists discuss how the EMERALD trial demonstrated elacestrant’s efficacy in ESR1-mutated tumors, particularly in patients who had received CDK4/6 inhibitors for at least 12 months. This led to its FDA approval for this specific...
« Older Entries
Next Entries »

Recent Content

  • Correction: Chen et al. The Efficacy and Safety of Tandem Transplant Versus Single Stem Cell Transplant for Multiple Myeloma Patients: A Systematic Review and Meta-Analysis. Diagnostics 2024, 14, 1030
  • Comparison of Standard of Care with or Without a PD-1/PD-L-1 Inhibitor for the Treatment of Multiple Myeloma: A Systematic Review and Meta-Analysis of Phase II and III Randomized Controlled Trials
  • Combo treatment may offer new hope to astrocytoma patients: Trial
  • Reduced-versus Standard-dose Melphalan as Single-agent Conditioning Regimen in Auto HSCT for Multiple Myeloma: A Systematic Review and Meta-Analysis
  • Dosing begins in trial testing Enhertu for ovarian cancer
  • (no title)
  • (no title)
  • Teclistamab combo improves relapsed, refractory myeloma outcomes
  • Safety and Efficacy of Anti-B-cell Maturation Antigen (Anti-BCMA) Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma: A Systematic Review of Clinical Trials
  • (no title)
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT